NovoCure Ltd (NASDAQ:NVCR) reported a first-quarter 2025 loss of 31 cents, down from the 36-cent loss reported a year ago, beating the consensus loss of 46 cents.

Sales increased 12% year over year to $155 million, beating the consensus of $146.6 million.

• The U.S., Germany, France, and Japan contributed $93.2 million, $18.7 million, $17.9 million, and $8.7 million, respectively, while other active markets contributed $11.9 million.
• Revenue in Greater China from Novocure’s partnership with Zai Lab totaled $4.6 million.
• Recognized revenue from Optune Lua in the quarter was $1.5 million, including $0.8 million from malignant pleural mesothelioma and $0.7 million from metastatic non-small cell lung cancer.

Also Read: Bristol Myers Delivers Upbeat 2025 Forecast Despite China Tariffs Impact

On Thursday, the company said the global tariff environment is changing rapidly. In April, the U.S. temporarily delayed the implementation of new tariffs by 90 days, resulting in a 10% tariff for most countries.

If the current pause is extended through year-end, Novocure could see an increase in import duties of up to $8 million in 2025.

If the tariffs return to pre-April 9 rates after the current 90-day pause, Novocure could see an increase in import duties of up to $11 million in 2025.

Novocure is closely monitoring the evolving tariff landscape to mitigate impacts on our supply chain costs where possible.

As of March 31, 2025, there were 4,268 total active patients on TTFields therapy globally.

Optune Gio: In the quarter, 1,608 prescriptions for Optune Gio for glioblastoma were received, a decrease of 1% from a year ago:

• The U.S., Germany, France, and Japan contributed 908, 198, 207, and 118 prescriptions, respectively, with the remaining 177 prescriptions contributed by other active markets. There were 4,162 active Optune Gio patients on therapy, an increase of 9%.
• The U.S., Germany, France, and Japan contributed 2,157, 573, 463, and 445 Optune Gio active patients, respectively, with the remaining 524 active patients contributed by other active markets.

Optune Lua: 127 total prescriptions for Optune Lua were received. 92 were for metastatic NSCLC, and 35 were for malignant pleural mesothelioma.

• As of March 31, 2025, 106 active Optune Lua patients were on therapy, including 62 patients treated for metastatic NSCLC patients and 44 for malignant pleural mesothelioma.

On Tuesday, Novocure’s Optune Lua received a CE Mark for adult patients with metastatic non-small cell lung cancer (NSCLC) concurrently with immune checkpoint inhibitors or docetaxel who have progressed on or after a platinum-based regimen.

Price Action: NVCR stock is down 0.81% at $17.63 at the last check on Thursday.

Read Next:

• Merck’s Q1 Earnings Beat Wall Street, Adjusts 2025 Profit Outlook As Tariffs May Result In Incremental Cost Of $200 Million